药物洗脱支架对冠状动脉临界病变合并易损斑块干预的临床预后

摘要

目的 探讨药物洗脱支架联合标准药物治疗与单纯标准药物治疗对冠状动脉临界病变合并易损斑块干预的临床预后研究.方法 连续入选2011年7月至2016年1月住院的冠状动脉临界病变合并易损斑块患者327例,临界病变指冠脉造影50%<冠脉直径狭窄<70%,64排冠脉CT检测易损斑块.随机分为药物洗脱支架联合标准药物治疗组(支架组)与单纯标准药物治疗组(药物组),随访1年内主要心脏不良事件MACE(死亡、心梗、靶血管再次血运重建).结果 支架组成功随访160例,5例出现MACE;药物组成功随访160例,16例出现MACE,支架组较药物组MACE减少,差异具有统计学意义(3.13%vs.10%,log-rank检验χ2=6.62,P=0.01);支架组较药物组死亡、心梗减少,差异具有统计学意义(1.25%vs.5.63%,log-rank检验χ2=4.61,P=0.03).结论 对于冠状动脉临界病变合并易损斑块的处理策略,药物洗脱支架联合标准药物治疗较单纯标准药物治疗可以减少MACE.%Objective To evaluate the one-year clinical outcomes in patients with the vulnerable plaque sealing with drug-eluting stents for the treatment of intermediate coronary stenosis. Methods 327 patients with an-giographically intermediate lesions(diameter stenosis 50%~70%)with the vulnerable plaque which were detected by 64 slice coronary CT were prospectively enrolled. Patients were divided into medical therapy group (n = 160) and sirolimus-eluting stent group group(n=160). The incidences of one-year major adverse cardiovascular events (MACE)was evaluated(cardiac death,myocardial infarction ,revascularization). Results The MACE tended to be lower in the sirolimus-eluting stent group than medical therapy group(3.13%vs. 10%,log-rankχ2=6.62,P=0.01). The incident of cardiac death and myocardial infarction were lower in the sirolimus-eluting stent group than medical therapy group(1.25%vs. 5.63%,log-rankχ2=4.61,P=0.03). Conclusion The treatment of the siroli-mus-eluting stent can reduce MACE for the paitents with the vulnerable plaque of intermediate coronary stenosis than medical therapy only.